News | Contrast Media | March 24, 2021

Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI)

Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI)

March 24, 2021 — Guerbet announced positive results from two Phase III clinical studies comparing the diagnostic efficacy and safety of Gadopiclenol to Gadobutrol in a wide range of indications, covering the central nervous system and various other anatomical areas (head and neck, thorax, abdomen, pelvis, musculoskeletal system).

A total of 560 patients were recruited for these two studies in over 60 hospital medical imaging departments in 13 countries.

The endpoints were met in terms of the diagnostic benefit of injecting Gadopiclenol (0.05 mmol/kg) during MRI examinations, based on: 1/ the superiority of the examination with Gadopiclenol compared to the examination with no contrast agent; and 2/ the non-inferiority of Gadopiclenol (0.05 mmol/kg) compared to Gadobutrol (0.1 mmol/kg) for the visualization and detection of lesions of the central nervous system and in the other anatomical areas studied.

In addition to these Phase III trials, a study was conducted on 80 children between 2 and 17 years of age in 19 centers in five European countries. This study showed that the pharmacokinetic profile of Gadopiclenol at 0.05 mmol/kg in children was similar to that of adults. It will therefore be possible to extrapolate the efficacy of Gadopiclenol to the pediatric population based on data collected in adult patients.

No major safety signals were reported during the development of Gadopiclenol, and the adverse reactions reported during the two Phase III studies were similar for both of the products administered.

"We are very happy with the results of these studies, which demonstrate the diagnostic value and good tolerance of Gadopiclenol during an MRI examination in adults and children. By using a lower dose of gadolinium in clinical practice, we hope this macrocyclic contrast agent will become a 'best-in-class' diagnostic solution for doctors and their patients." said David Hale, CEO of Guerbet. 

All this data will serve as a basis for regulatory submissions, which will begin in the United States and in the European Union (EU) early 2022.

For more information: www.guerbet.com

 

Related Content

News | Coronavirus (COVID-19)

January 14, 2022 — The COVID-19 pandemic took the world by storm in early 2020 and has become since then the leading ...

Time January 14, 2022
arrow
News | Radiology Business

January 13, 2022 — The Board of Directors of Esaote, a leading Italian company in the biomedical sector – in ultrasound ...

Time January 13, 2022
arrow
News | Pediatric Imaging

January 12, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), whole-spine MRI commonly ...

Time January 12, 2022
arrow
News | Radiology Imaging

January 12, 2022 — Machine-learning methods are being actively developed for computed imaging systems like magnetic ...

Time January 12, 2022
arrow
News | Computed Tomography (CT)

January 6, 2022 — Royal Philips announced new additions to its CT imaging portfolio at the Radiological Society of North ...

Time January 06, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

January 5, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), brain volume measurements in ...

Time January 05, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

January 5, 2022 — A new neuroimaging technique can detect biochemical changes in the brains of people with multiple ...

Time January 05, 2022
arrow
News | RSNA

January 5, 2022 — The Radiological Society of North America’s 107th Scientific Assembly and Annual Meeting (RSNA 2021) ...

Time January 05, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

January 5, 2022 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved new expanded magnetic ...

Time January 05, 2022
arrow
News | Ultrasound Imaging

January 4, 2022 — The future of ultrasound is happening — fast — and it doesn’t cost that much more than an iPhone. At ...

Time January 04, 2022
arrow
Subscribe Now